Abstract
The cellular composition of the tumor microenvironment can directly impact cancer progression and the efficacy of therapeutics. Understanding immune cell activity, the body's natural defense mechanism, in the vicinity of cancerous cells is essential for developing beneficial treatments. Single cell RNA sequencing (scRNA-seq) enables the examination of gene expression on an individual cell basis, providing crucial information regarding both the disturbances in cell functioning caused by cancer and cell-cell communication in the tumor microenvironment. This novel technique generates large amounts of data, which require proper processing. Various tools exist to facilitate this processing but need to be organized to standardize the workflow from data wrangling to visualization, cell type identification, and analysis of changes in cellular activity, both from the standpoint of malignant cells and immune stromal cells that eliminate them. We aimed to develop a standardized pipeline (GeoTyper, https://github.com/celineyayifeng/GeoTyper) that integrates multiple scRNA-seq tools for processing raw sequence data extracted from NCBI GEO, visualization of results, statistical analysis, and cell type identification. This pipeline leverages existing tools, such as Cellranger from 10X Genomics, Alevin, and Seurat, to cluster cells and identify cell types based on gene expression profiles. We successfully tested and validated the pipeline on several publicly available scRNA-seq datasets, resulting in clusters corresponding to distinct cell types. By determining the cell types and their respective frequencies in the tumor microenvironment across multiple cancers, this workflow will help quantify changes in gene expression related to cell-cell communication and identify possible therapeutic targets.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.